bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Authors: Kuo Peiwen , Bratman Scott V. , Shultz David B. , von Eyben Rie , Chan Cato , Wang Ziwei , Say Carmen , Gupta Aparna , Loo Bill W. , Giaccia Amato J. , Koong Albert C. , Diehn Maximilian , Le Quynh-Thu
Published: April 2023

Lymphocytes from Gal-1 WT and null mice exhibiting similar sensitivity to ionizing radiation and recombinant Gal-1.
Supplementary Movie S1 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Movie S1. To model human laparoscopic tumor resection, athymic Nu/Nu mice harboring PSMA-positive xenografts were administered 19.1 μg/kg (HED of 100 μg for a 70 Kg male) YC-27 via tail vein injection. The mice were placed in a laparoscopic training box, and the PSMA-positive xenografts were resected 10 hours after injection of YC-27 with the guidance of the LumiNIR{trade mark, serif} system. Imaging was done using a 830nm laser to visualize the whole animal and 780nm laser to identify the PSMA-positive xenograft.
Supplementary Methods from Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies
Authors: Pollock Netanya I. , Wang Lin , Wallweber Gerald , Gooding William E. , Huang Weidong , Chenna Ahmed , Winslow John , Sen Malabika , DeGrave Kara A. , Li Hua , Zeng Yan , Grandis Jennifer R.
Published: April 2023

Detailed methods for VeraTag assays.
Supplementary Table S2 from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia
Authors: Seipel Katja , Marques Miguel Teixera , Bozzini Marie-Ange , Meinken Christina , Mueller Beatrice U. , Pabst Thomas
Published: April 2023

Table S2: Assessment of cell cycle stages, apoptosis and differentiation markers in OCI-AML3 cells after 24hrs of treatment (�lls).
Supplementary Table 2 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Authors: Attard Gerhardt , de Bono Johann S. , Logothetis Christopher J. , Fizazi Karim , Mukherjee Som D. , Joshua Anthony M. , Schrijvers Dirk , van den Eertwegh Alfons J.M. , Li Weimin , Molina Arturo , Griffin Thomas W. , Kheoh Thian , Ricci Deborah S. , Zelinsky Kathy , Rathkopf Dana E. , Scher Howard I. , Ryan Charles J.
Published: April 2023

Supplementary Table 2. Radiographic progression-free survival and overall survival by ERG class
Supplementary Figure 4 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Authors: Attard Gerhardt , de Bono Johann S. , Logothetis Christopher J. , Fizazi Karim , Mukherjee Som D. , Joshua Anthony M. , Schrijvers Dirk , van den Eertwegh Alfons J.M. , Li Weimin , Molina Arturo , Griffin Thomas W. , Kheoh Thian , Ricci Deborah S. , Zelinsky Kathy , Rathkopf Dana E. , Scher Howard I. , Ryan Charles J.
Published: April 2023

Supplementary Figure 4. ERG FISH break apart assay
Data Supplement from CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplemental Figure Legend
Data Supplement from RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplementary Figure 3 - Proliferation and colony formation assays of gastric cancer monolayer cells and spheroid cells.
Supplementary Figures S1-S5 from Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients
Authors: Lee Keun-Wook , Lee Sung Sook , Kim Sang-Bae , Sohn Bo Hwa , Lee Hyun-Sung , Jang Hee-Jin , Park Yun-Yong , Kopetz Scott , Kim Sung Soo , Oh Sang Cheul , Lee Ju-Seog
Published: April 2023

Supplementary Figures S1-S5. Supplementary Figure S1. Expression of YAP1 in NCI-H716 CRC cells. Supplementary Figure S2. YAP1-specific gene expression signature used in our study of YAP1 activation in CRC patients. Supplementary Figure S3. Gene set enrichment analysis (GSEA) of gene expression data from two cancer cells with activated YAP1. Supplementary Figure S4. Prognostic impact of the YAP1 signature for CRC according to disease stages. Supplementary Figure S5. PFS according to KRAS mutation status (Cohort 5)
Supplementary Table 2 from Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
Authors: Rothenberg S. Michael , McFadden David G. , Palmer Edwin L. , Daniels Gilbert H. , Wirth Lori J.
Published: April 2023

Supplementary Table 2. Spot Urine Iodide Measurements.
Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

Supplementary Table 1A. Patient characteristics (n=145). Supplementary Table 1B. EGFR mutation types (n=44). Supplementary Table 2A. Univariate Cox regression analysis. Supplementary Table 2B. Multivariate Cox regression analysis.
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 1 from A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Authors: Schlumberger Martin , Jarzab Barbara , Cabanillas Maria E. , Robinson Bruce , Pacini Furio , Ball Douglas W. , McCaffrey Judith , Newbold Kate , Allison Roger , Martins Renato G. , Licitra Lisa F. , Shah Manisha H. , Bodenner Donald , Elisei Rossella , Burmeister Lynn , Funahashi Yasuhiro , Ren Min , O'Brien James P. , Sherman Steven I.
Published: April 2023

Tumor response
Supplementary Figure 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Authors: Garcia Jacqueline S. , Huang Min , Medeiros Bruno C. , Mitchell Beverly S.
Published: April 2023

(A) Cytotoxicity of ixazomib compared to MLN2238 (IC50 = 63.68 {plus minus} 5.3 nM) in OCI-AML3 cells. Plots of (B) GFP expression by K562 cells ectopically expressing constructs (C) treated with ixazomib.
Supplementary Table 1 from Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Authors: Gainor Justin F. , Tan Daniel S.W. , De Pas Tomasso , Solomon Benjamin J. , Ahmad Aziah , Lazzari Chiara , de Marinis Filippo , Spitaleri Gianluca , Schultz Katherine , Friboulet Luc , Yeap Beow Y. , Engelman Jeffrey A. , Shaw Alice T.
Published: April 2023

Supplementary Table 1. Summary of Interval Systemic Anticancer Therapies Received by ALK-Positive Patients Between Crizotinib and Ceritinib
Interaction of sfRon and the p85a subunit of PI3K in MCF7-sfRon cells and breast cancer PDX tumors from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
Authors: Bieniasz Magdalena , Radhakrishnan Parvathi , Faham Najme , De La O Jean-Paul , Welm Alana L.
Published: April 2023

Representative co-IP Western blot showing interaction between sfRon and the p85a subunit of PI3K in MCF7-sfRon cells treated with DMSO or increasing amounts of ASALAN002, and in tumors harvested from NOD/SCID mice bearing HCI-011 (PIK3CAWT) PDX. Mice bearing PDXs received a single dose of ASLAN002 (50 mg/kg) or vehicle and tumors were harvested 3 h later. For co-immunprecipititation studies, whole-cell extracts were immunoprecipitated with anti-p85a antibody followed by Western blot with anti-Ron antibody. Results indicate that inhibition of sfRon in both MCF7 cells and PDX tumors leads to dissociation of p85a subunit of PI3K from sfRon. The mock IP represents the same conditions as the other IPs, but without inclusion of protein lysate.
Supplemental Methods from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Authors: Schuller Alwin G. , Barry Evan R. , Jones Rhys D.O. , Henry Ryan E. , Frigault Melanie M. , Beran Garry , Linsenmayer David , Hattersley Maureen , Smith Aaron , Wilson Joanne , Cairo Stefano , Déas Olivier , Nicolle Delphine , Adam Ammar , Zinda Michael , Reimer Corinne , Fawell Stephen E. , Clark Edwin A. , D'Cruz Celina M.
Published: April 2023

Supplemental Methods. Methods used to generate supplemental data
Supplemental Figure 1 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Authors: Schuller Alwin G. , Barry Evan R. , Jones Rhys D.O. , Henry Ryan E. , Frigault Melanie M. , Beran Garry , Linsenmayer David , Hattersley Maureen , Smith Aaron , Wilson Joanne , Cairo Stefano , Déas Olivier , Nicolle Delphine , Adam Ammar , Zinda Michael , Reimer Corinne , Fawell Stephen E. , Clark Edwin A. , D'Cruz Celina M.
Published: April 2023

Supplemental Figure 1. In vitro activity of AZD6094, sunitinib, crizotinib, SGX-523, JNJ3887605, PHA-665752, and INC280 in AGS and GTL16 gastric cancer cells
Supplementary Table 2 from Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer
Authors: Sanz-Pamplona Rebeca , Lopez-Doriga Adriana , Paré-Brunet Laia , Lázaro Kira , Bellido Fernando , Alonso M. Henar , Aussó Susanna , Guinó Elisabet , Beltrán Sergi , Castro-Giner Francesc , Gut Marta , Sanjuan Xavier , Closa Adria , Cordero David , Morón-Duran Francisco D. , Soriano Antonio , Salazar Ramón , Valle Laura , Moreno Victor
Published: April 2023

List of primers used in Sanger sequencing and SNPs utilized to genotype the 84 normal adjacent and tumor samples.
Supplemental Methods and Results from Global Promoter Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes in Natural Killer Cell Lymphoma
Authors: Küçük Can , Hu Xiaozhou , Jiang Bei , Klinkebiel David , Geng Huimin , Gong Qiang , Bouska Alyssa , Iqbal Javeed , Gaulard Philippe , McKeithan Timothy W. , Chan Wing C.
Published: April 2023

Supplemental Methods and Results. Supplemental file including methods for GEP, RRBS, pyrosequencing, q-RT-PCR, western blot, functional assays, additional statistical methods and results describing the enrichment of tumor suppressor genes among epigenetically silenced genes
Supplementary Tables 1 - 3, Figures 1 - 4 from Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Authors: Egloff Ann Marie , Lee Ju-Whei , Langer Corey J. , Quon Harry , Vaezi Alec , Grandis Jennifer R. , Seethala Raja R. , Wang Lin , Shin Dong M. , Argiris Athanassios , Yang Donghua , Mehra Ranee , Ridge John Andrew , Patel Urjeet A. , Burtness Barbara A. , Forastiere Arlene A.
Published: April 2023

Supplemental Table 1. Criteria for Unresectable Disease Supplemental Table 2. Modified RECIST Criteria for Head and Neck Cancer. Supplemental Table 3. Summary of Serum Analyte Levels. Supplemental Figure 1. Study Schematic Supplemental Figure 2. Time to locoregional failure for all eligible and treated patients (a) and by tumor HPV status (b). Log rank test comparing time to failure for HPV+ versus HPV- p value provided. Supplemental Figure 3. Representative tissue cores with high or low expression levels of XPF or ERCC1 as assessed by AQUA. Tumors were stained for cytokeratin (CK) to create a tumor mask and with DAPI to define the nuclear compartment. Supplemental Figure 4. Representative tumor IHC molecular correlates ERCC1, XPF and MET.
Supplementary table S4 from Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
Authors: Lee Hye Won , Lee Jung-il , Lee Se Jeong , Cho Hyun Jung , Song Hye Jin , Jeong Da Eun , Seo Yun Jee , Shin Sang , Joung Je-Gun , Kwon Yong-Jun , Choi Yoon-La , Park Woong-Yang , Lee Hyun Moo , Seol Ho Jun , Shim Young Mog , Joo Kyeung Min , Nam Do-Hyun
Published: April 2023

Supplementary table S4. Clinicopathological characteristics and in vivo tumorigenicity of brain metastatic NSCLC cases.
Supplementary Figure 1 from Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Authors: Tewari Krishnansu S. , Sill Michael W. , Monk Bradley J. , Penson Richard T. , Long Harry J. , Poveda Andrés , Landrum Lisa M. , Leitao Mario M. , Brown Jubilee , Reid Thomas J.A. , Michael Helen E. , Moore David H.
Published: April 2023

This Supplementary Figure contains the GOG 240 trial schema along with the survival curves from the interim analysis and second analysis.
Supplemental Figure S1 and Table S1 from A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
Authors: Lassen Ulrik N. , Meulendijks Didier , Siu Lilian L. , Karanikas Vaios , Mau-Sorensen Morten , Schellens Jan H.M. , Jonker Derek J. , Hansen Aaron R. , Simcox Mary E. , Schostack Kathleen J. , Bottino Dean , Zhong Hua , Roessler Markus , Vega-Harring Suzana M. , Jarutat Tiantom , Geho David , Wang Ka , DeMario Mark , Goss Glenwood D.
Published: April 2023

Supplemental Figure S1 and Table S1. Figure S1: RG7212 phase I study flow diagram and treatment schema. Table S1. Summary of Fn14 Testing and Positivity Rate (IHC{greater than or equal to}1+) for the Most Commonly Screened Solid Tumors
Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Authors: Ortiz-Cuaran Sandra , Scheffler Matthias , Plenker Dennis , Dahmen llona , Scheel Andreas H. , Fernandez-Cuesta Lynnette , Meder Lydia , Lovly Christine M. , Persigehl Thorsten , Merkelbach-Bruse Sabine , Bos Marc , Michels Sebastian , Fischer Rieke , Albus Kerstin , König Katharina , Schildhaus Hans-Ulrich , Fassunke Jana , Ihle Michaela A. , Pasternack Helen , Heydt Carina , Becker Christian , Altmüller Janine , Ji Hongbin , Müller Christian , Florin Alexandra , Heuckmann Johannes M. , Nuernberg Peter , Ansén Sascha , Heukamp Lukas C. , Berg Johannes , Pao William , Peifer Martin , Buettner Reinhard , Wolf Jürgen , Thomas Roman K. , Sos Martin L.
Published: April 2023

Targeted and Sanger sequencing results at the EGFR locus for P6 and P7.
Supplementary Figure 6. RET expression by immunohistochemistry. from RET Signaling in Prostate Cancer
Authors: Ban Kechen , Feng Shu , Shao Longjiang , Ittmann Michael
Published: April 2023

A. Adrenal medulla, which was used as a RET positive control. Adrenal cortex is at the bottom of the field (100x). B. Second transurethral resection of small cell carcinoma of the prostate expressing RET (400X). C. Primary small intestinal carcinoid expressing RET (200X). Note heterogeneous staining with some areas not staining (arrowhead). D. Small cell carcinoma of lung (400X).
Supplemental Figure 5 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
Authors: Van Roosbroeck Katrien , Fanini Francesca , Setoyama Tetsuro , Ivan Cristina , Rodriguez-Aguayo Cristian , Fuentes-Mattei Enrique , Xiao Lianchun , Vannini Ivan , Redis Roxana S. , D'Abundo Lucilla , Zhang Xinna , Nicoloso Milena S. , Rossi Simona , Gonzalez-Villasana Vianey , Rupaimoole Rajesha , Ferracin Manuela , Morabito Fortunato , Neri Antonino , Ruvolo Peter P. , Ruvolo Vivian R. , Pecot Chad V. , Amadori Dino , Abruzzo Lynne , Calin Steliana , Wang Xuemei , You M. James , Ferrajoli Alessandra , Orlowski Robert , Plunkett William , Lichtenberg Tara M. , Davuluri Ramana V. , Berindan-Neagoe Ioana , Negrini Massimo , Wistuba Ignacio I. , Kantarjian Hagop M. , Sood Anil K. , Lopez-Berestein Gabriel , Keating Michael J. , Fabbri Muller , Calin George A.
Published: April 2023

Supplementary Table S1 Clinical characteristics of two chronic lymphocytic leukemia patient datasets; Supplementary Table S2 Clinical characteristics of two lung cancer patient datasets; Supplementary Table S3 Clinical characteristics of the ALL dataset; Supplementary Table S4 Integrated function and pathway analysis on 248 experimentally validated targets of miR-155; Supplementary Table S5 Univariate and multivariate analyses of survival with patient characteristics and miR-155 and TP53 expression as categorical and continuous variables in different patient cohorts; Supplementary Table S6 Estimate of Cox model and multivariate Cox model, as well as the HR estimated based on the model for miR-155 high and TP53 low vs. miR-155 low and TP53 high.
Figure S4 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

Kaplan Meier overall survival curves by PIK3CA, CDKN2A and TP53 allelic mutation state
Supplementary Table 1 from Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805
Authors: Jilaveanu Lucia B. , Puligandla Maneka , Weiss Sarah A. , Wang Xin Victoria , Zito Christopher , Flaherty Keith T. , Boeke Marta , Neumeister Veronique , Camp Robert L. , Adeniran Adebowale , Pins Michael , Manola Judith , DiPaola Robert S. , Haas Naomi B. , Kluger Harriet M.
Published: April 2023

Multivariable analysis of clinical and pathologic variables and their association with overall survival in RCC
Supplementary Figure and Tables legends from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Authors: Becht Etienne , de Reyniès Aurélien , Giraldo Nicolas A. , Pilati Camilla , Buttard Bénédicte , Lacroix Laetitia , Selves Janick , Sautès-Fridman Catherine , Laurent-Puig Pierre , Fridman Wolf Herman
Published: April 2023

Legends for supplementary figure and trables
Table S1 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
Authors: Sun Jie , Meng Hua , Yao Lu , Lv Meng , Bai Jian , Zhang Jianguang , Wang Lientu , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

Categories of the 46 Cancer Susceptibility Genes
Table S3 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

Baseline gene expression analysis of B cell lymphoma cell lines with higher (IC50 < 200 nM) or lower sensitive (IC50 > 400 nM) to PQR309.
Supplementary Table 2a and 2b from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Main characteristics of evaluable clinical studies included in meta-analysis for disease free survival (DFS) and overall survival (OS)
Supplementary Figure 2A from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Correlation of clinical variables and AR mRNA expression in all BC patients
Supplementary Table S1 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

Clinical details of patients with ovarian tumors contributing to data from blood and ascites. Eight women with EOC donated only ascites (no blood or tissue) and they are not shown in this table (see supplementary figure S1).
Supplementary Table S4 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

Demographic and clinical-pathologic characteristics of eligible patients in intermediate/high risk radical prostatectomy cohort
Supplementary Table S3 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

TP53 mutations in formalin fixed paraffin embedded primary and metastatic prostate tumors stratified by immunohistochemistry (IHC) result. Bolded results indicate discordant samples. Red font indicates disruptive mutations by Poeta et al criteria (reference 42).
C-statistics by tumor histology from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
Authors: Terry Kathryn L. , Schock Helena , Fortner Renée T. , Hüsing Anika , Fichorova Raina N. , Yamamoto Hidemi S. , Vitonis Allison F. , Johnson Theron , Overvad Kim , Tjønneland Anne , Boutron-Ruault Marie-Christine , Mesrine Sylvie , Severi Gianluca , Dossus Laure , Rinaldi Sabina , Boeing Heiner , Benetou Vassiliki , Lagiou Pagona , Trichopoulou Antonia , Krogh Vittorio , Kuhn Elisabetta , Panico Salvatore , Bueno-de-Mesquita H. Bas , Onland-Moret N. Charlotte , Peeters Petra H. , Gram Inger Torhild , Weiderpass Elisabete , Duell Eric J. , Sanchez Maria-Jose , Ardanaz Eva , Etxezarreta Nerea , Navarro Carmen , Idahl Annika , Lundin Eva , Jirström Karin , Manjer Jonas , Wareham Nicholas J. , Khaw Kay-Tee , Byrne Karl Smith , Travis Ruth C. , Gunter Marc J. , Merritt Melissa A. , Riboli Elio , Cramer Daniel W. , Kaaks Rudolf
Published: April 2023

C-statistics by tumor histology for variable lag-times since blood donation
Table S2 from 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Authors: Quintela-Fandino Miguel , Lluch Ana , Manso Luis , Calvo Isabel , Cortes Javier , García-Saenz José Angel , Gil-Gil Miguel , Martinez-Jánez Noelia , Gonzalez-Martin Antonio , Adrover Encarna , de Andres Raquel , Viñas Gemma , Llombart-Cussac Antonio , Alba Emilio , Guerra Juan , Bermejo Begoña , Zamora Esther , Moreno-Anton Fernando , Pernas Simon Sonia , Carrato Alfredo , Lopez-Alonso Antonio , Escudero María José , Campo Ruth , Carrasco Eva , Palacios José , Mulero Francisca , Colomer Ramon
Published: April 2023

Response data description
Supplementary Figure 1 from 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Authors: Quintela-Fandino Miguel , Lluch Ana , Manso Luis , Calvo Isabel , Cortes Javier , García-Saenz José Angel , Gil-Gil Miguel , Martinez-Jánez Noelia , Gonzalez-Martin Antonio , Adrover Encarna , de Andres Raquel , Viñas Gemma , Llombart-Cussac Antonio , Alba Emilio , Guerra Juan , Bermejo Begoña , Zamora Esther , Moreno-Anton Fernando , Pernas Simon Sonia , Carrato Alfredo , Lopez-Alonso Antonio , Escudero María José , Campo Ruth , Carrasco Eva , Palacios José , Mulero Francisca , Colomer Ramon
Published: April 2023

CONSORT DIAGRAM
Supplemental Figures and Legends from Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway
Authors: Bartkowiak Todd , Jaiswal Ashvin R. , Ager Casey R. , Chin Renee , Chen Chao-Hsien , Budhani Pratha , Ai Midan , Reilley Matthew J. , Sebastian Manu M. , Hong David S. , Curran Michael A.
Published: April 2023

Supplemental Figure 1: Peak of 4-1BB mediate liver transaminase level and gating strategy for flow cytometry analysis of liver immune infiltrates. Supplemental Figure 2: Representative flow cytometry analysis of liver immune infiltrates. Supplemental Figure 3: Administration of 4-1BB agonist antibodies initiates liver pathology through activation of liver-resident myeloid cells. Supplemental Figure 4: Effects of IL-27 pathway inactivation on CD4 T cells. Supplemental Figure 5: Representative flow cytometry analysis of liver immune infiltrates.
Supplemental Table 2 from The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
Authors: Salomon Matthew P. , Wang Xiaowen , Marzese Diego M. , Hsu Sandy C. , Nelson Nellie , Zhang Xin , Matsuba Chikako , Takasumi Yuki , Ballesteros-Merino Carmen , Fox Bernard A. , Barkhoudarian Garni , Kelly Daniel F. , Hoon Dave S.B.
Published: April 2023

Table of significant SCNAs among PAs. This table highlights the top 10 most significant GISTIC2 calls for all PAs in this study, each PA subtype, and invasive versus non-invasive PAs.
Supplemental Figure 1 from Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Authors: Tang Chad , Sherman Steven I. , Price Mellanie , Weng Jun , Davis Suzanne E. , Hong David S. , Yao James C. , Buzdar Aman , Wilding George , Lee J. Jack
Published: April 2023

Trial Inclusion Diagram
Figure S7 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

cAMP levels
Figure S5 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

murine toxicity
Table S1 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

List of the 94 genes with increased expression levels in both MCF-7TAM and MCF-7RT
Figure S1 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

PDE4B WB
Supplementary Figures from Recurrent TRIO Fusion in Nontranslocation–Related Sarcomas
Authors: Delespaul Lucile , Lesluyes Tom , Pérot Gaëlle , Brulard Céline , Lartigue Lydia , Baud Jessica , Lagarde Pauline , Le Guellec Sophie , Neuville Agnès , Terrier Philippe , Vince-Ranchère Dominique , Schmidt Susanne , Debant Anne , Coindre Jean-Michel , Chibon Frédéric
Published: April 2023

Supplementary Figure 1: Identification of FARSA-SYCE2 and GSE1-RP11-680G10.1 read-throughs in sarcoma CL1 and normal tissue. Supplementary Figure 2: aCGH (SNP-array) profile of CL1 which present a genomic rearrangement of TRIO and TERT genes. Supplementary Figure 3: Expression percentage of the two TRIO-TERT isoforms in three cases. Supplementary Figure 4: Predicted acceptor splicing regions in intron 2 and 3 of LINC01504. Supplementary Figure 5: Transcriptomic profile clustering of the 117 non-translocation-related sarcomas. Supplementary Figure 6: Volcano plot of the 117 sarcomas with six fused TRIO cases versus 111 non-fused TRIO cases. Supplementary Figure 7: Exonic expression of fused TRIO fused and non-fused TRIO cases.Supplementary Figure 8: Enrichment plot for significant Hallmarks in six fused TRIO samples included in the MSig5.0 database according to GSEA. Supplementary Figure 9: Enrichment plot for significant Hallmarks in 111 non-fused TRIO samples included in the MSig5.0 database according to GSEA. Supplementary Figure 10: ALT mechanism status determined by PML/TERF2 immunofluorescence analysis.
Supplemental Data from Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer
Authors: Mishra Rasmi R. , Belder Nevin , Ansari Suhail A. , Kayhan Merve , Bal Hilal , Raza Umar , Ersan Pelin G. , Tokat Ünal M. , Eyüpoğlu Erol , Saatci Özge , Jandaghi Pouria , Wiemann Stefan , Üner Ayşegül , Cekic Caglar , Riazalhosseini Yasser , Şahin Özgür
Published: April 2023

This file contains supplementary methods, 7 supplementary figures and 5 supplementary tables.
Conflict of Interest Patent Info from Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer
Authors: Mishra Rasmi R. , Belder Nevin , Ansari Suhail A. , Kayhan Merve , Bal Hilal , Raza Umar , Ersan Pelin G. , Tokat Ünal M. , Eyüpoğlu Erol , Saatci Özge , Jandaghi Pouria , Wiemann Stefan , Üner Ayşegül , Cekic Caglar , Riazalhosseini Yasser , Şahin Özgür
Published: April 2023

Mishra and Sahin patent info for Conflict of Interest
Suppl. Methods Figure Legends from Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
Authors: Odate Seiichi , Veschi Veronica , Yan Shuang , Lam Norris , Woessner Richard , Thiele Carol J.
Published: April 2023

Supplementary information on Methods and Figure legends for Supplementary Figures.
Figures S1-3 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

Supplemental Figure 1. COV434-pIND20-Brg1 SMARCA4 induction optimization; Supplemental Figure 2. Kinase hits from siRNA screen mapped to kinome dendrogram; Supplemental Figure 3. ClueGo analysis of validated siRNA screen hits.
Figure S1 from Establishing a Preclinical Multidisciplinary Board for Brain Tumors
Authors: Nimmervoll Birgit V. , Boulos Nidal , Bianski Brandon , Dapper Jason , DeCuypere Michael , Shelat Anang , Terranova Sabrina , Terhune Hope E. , Gajjar Amar , Patel Yogesh T. , Freeman Burgess B. , Onar-Thomas Arzu , Stewart Clinton F. , Roussel Martine F. , Guy R. Kipling , Merchant Thomas E. , Calabrese Christopher , Wright Karen D. , Gilbertson Richard J.
Published: April 2023

Tumor proliferation measured as Ki67 index in (A) mSEP-CR(-)RTBDNb and (B) mCPC treated with the indicated dose and route of administration of gemcitabine.
Supplementary Data from Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1
Authors: Soulières Denis , Licitra Lisa , Mesía Ricard , Remenár Éva , Li Shau-Hsuan , Karpenko Andrey , Chol Marie , Wang Ying A. , Solovieff Nadia , Bourdeau Laurence , Sellami Dalila , Faivre Sandrine
Published: April 2023

Supplementary methods and results Supplementary Table 1: Mutational profiles of patients with HPV-positive vs HPV-negative tumors Supplementary Figure 1: Interaction between immune markers and other biomarkers
Supplementary Figures from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Authors: Dubois Sydney , Viailly Pierre-Julien , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Marchand Vinciane , Maingonnat Catherine , Mareschal Sylvain , Picquenot Jean-Michel , Penther Dominique , Jais Jean-Philippe , Tesson Bruno , Peyrouze Pauline , Figeac Martin , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Fabiani Bettina , Delarue Richard , Peyrade Frédéric , André Marc , Ketterer Nicolas , Leroy Karen , Salles Gilles , Molina Thierry J. , Tilly Hervé , Jardin Fabrice
Published: April 2023

Supplementary Figures 1-10 Figure S1. MYD88 mutation VAF according to L265P or non-L265P variants. Figure S2. Age according to MYD88 mutation status and variant among ABC patients. Figure S3. Genomic profiles of DLBCL according to the presence of MYD88 L265P or non-L265P variants. Figure S4. Relative L265P allele expression level according to L265P VAF. Figure S5. Gene expression according to MYD88 status. Figure S6. NFkB pathway gene expression according to MYD88 mutational status. Figure S7. LPS score according to subtype and downstream NFkB alterations. Figure S8. Clustering according to expression levels of 27 genes involved in LPS response and differentially expressed according to MYD88 L265P. Figure S9. TNFAIP3 and CARD11 expression according to their copy number status. Figure S10. Additional survival analyses.
Table S2 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Description of cohorts #1 and #2
Figure S6 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Association of VISTA expression with survival in NSCLC
Supplementary figure S7 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Authors: Luk Iris Sze Ue , Shrestha Raunak , Xue Hui , Wang Yuwei , Zhang Fang , Lin Dong , Haegert Anne , Wu Rebecca , Dong Xin , Collins Colin C. , Zoubeidi Amina , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Serum PSA (ng/ml) per unit tumour volume (mm3) in individual mice and in Scrb and ASO-6w2 groups
Supplementary figure S5 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Authors: Luk Iris Sze Ue , Shrestha Raunak , Xue Hui , Wang Yuwei , Zhang Fang , Lin Dong , Haegert Anne , Wu Rebecca , Dong Xin , Collins Colin C. , Zoubeidi Amina , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Weights of mice during treatment of LTL-313BR xenografts with ASO-6w2
Table S5 from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Authors: Garsed Dale W. , Alsop Kathryn , Fereday Sian , Emmanuel Catherine , Kennedy Catherine J. , Etemadmoghadam Dariush , Gao Bo , Gebski Val , Garès Valérie , Christie Elizabeth L. , Wouters Maartje C.A. , Milne Katy , George Joshy , Patch Ann-Marie , Li Jason , Arnau Gisela Mir , Semple Timothy , Gadipally Sreeja R. , Chiew Yoke-Eng , Hendley Joy , Mikeska Thomas , Zapparoli Giada V. , Amarasinghe Kaushalya , Grimmond Sean M. , Pearson John V. , Waddell Nicola , Hung Jillian , Stewart Colin J.R. , Sharma Raghwa , Allan Prue E. , Rambau Peter F. , McNally Orla , Mileshkin Linda , Hamilton Anne , Ananda Sumitra , Grossi Marisa , Cohen Paul A. , Leung Yee C. , Rome Robert M. , Beale Philip , Blomfield Penny , Friedlander Michael , Brand Alison , Dobrovic Alexander , Köbel Martin , Harnett Paul , Nelson Brad H. , Bowtell David D. L. , deFazio Anna
Published: April 2023

HR pathway mutations
Table S4 from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Authors: Garsed Dale W. , Alsop Kathryn , Fereday Sian , Emmanuel Catherine , Kennedy Catherine J. , Etemadmoghadam Dariush , Gao Bo , Gebski Val , Garès Valérie , Christie Elizabeth L. , Wouters Maartje C.A. , Milne Katy , George Joshy , Patch Ann-Marie , Li Jason , Arnau Gisela Mir , Semple Timothy , Gadipally Sreeja R. , Chiew Yoke-Eng , Hendley Joy , Mikeska Thomas , Zapparoli Giada V. , Amarasinghe Kaushalya , Grimmond Sean M. , Pearson John V. , Waddell Nicola , Hung Jillian , Stewart Colin J.R. , Sharma Raghwa , Allan Prue E. , Rambau Peter F. , McNally Orla , Mileshkin Linda , Hamilton Anne , Ananda Sumitra , Grossi Marisa , Cohen Paul A. , Leung Yee C. , Rome Robert M. , Beale Philip , Blomfield Penny , Friedlander Michael , Brand Alison , Dobrovic Alexander , Köbel Martin , Harnett Paul , Nelson Brad H. , Bowtell David D. L. , deFazio Anna
Published: April 2023

TP53 mutations
Table S3 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Authors: Yonesaka Kimio , Haratani Koji , Takamura Shiki , Sakai Hitomi , Kato Ryoji , Takegawa Naoki , Takahama Takayuki , Tanaka Kaoru , Hayashi Hidetoshi , Takeda Masayuki , Kato Sigeki , Maenishi Osamu , Sakai Kazuko , Chiba Yasutaka , Okabe Takafumi , Kudo Keita , Hasegawa Yoshikazu , Kaneda Hiroyasu , Yamato Michiko , Hirotani Kenji , Miyazawa Masaaki , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

Cox proportional hazard model for PFS
Table S2 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Authors: Yonesaka Kimio , Haratani Koji , Takamura Shiki , Sakai Hitomi , Kato Ryoji , Takegawa Naoki , Takahama Takayuki , Tanaka Kaoru , Hayashi Hidetoshi , Takeda Masayuki , Kato Sigeki , Maenishi Osamu , Sakai Kazuko , Chiba Yasutaka , Okabe Takafumi , Kudo Keita , Hasegawa Yoshikazu , Kaneda Hiroyasu , Yamato Michiko , Hirotani Kenji , Miyazawa Masaaki , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

Effect of PD-L1 and B7-H3 expression on response rate
supplement data from Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer
Authors: Yu Jiangyong , Wang Shuhang , Zhao Wei , Duan Jianchun , Wang Zhijie , Chen Hanxiao , Tian Yanhua , Wang Di , Zhao Jun , An Tongtong , Bai Hua , Wu Meina , Wang Jie
Published: April 2023

Supplemental Experimental Procedures The establishment of PDX models. Table S1. PDXs and corresponding clinical data Table S2: Antibody for Flow Cytometry. Table S3: qRT-PCR primer sequences. Table S4: Antibodies used in Western blots. Supplemental Experimental data Figure S1: Stem cell properties of Î±2Î'1+ H69 cells. Figure S2: The proportion of É'2Î'1+ and CD133+ cells in parental and 2nd generation PDXs Figure S3: Treatment curves of five PDX models Figure S4:Stem cell properties of Î±2Î'1+ Bclu80 cells. Figure S5: Differential genes and pathway enrichment in É'2Î'1 positive H1048 cells by RNA-Sequencing and analysis of protein interaction network. Table S5: Comparison of tumorigenic sufficiency for É'2Î'1/CD133 FACS-sorted H1048 cells in vivo. Table S6: Comparison of tumorigenic sufficiency for É'2Î'1 FACS-sorted H1048, H69 cells and Bclu80 PDX models in vivo. Table S7: Serial transplantation assay was performed into mice for validating self-renewal in vivo. Table S8: HE staining and immunochemistry results of SCLC patients and corresponding PDX models. Table S9. The differential expression genes of É'2Î'1+ and É'2Î'1- H1048 cells using RNA-Sequencing. Supplemental References
Figure S2 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Authors: Yonesaka Kimio , Haratani Koji , Takamura Shiki , Sakai Hitomi , Kato Ryoji , Takegawa Naoki , Takahama Takayuki , Tanaka Kaoru , Hayashi Hidetoshi , Takeda Masayuki , Kato Sigeki , Maenishi Osamu , Sakai Kazuko , Chiba Yasutaka , Okabe Takafumi , Kudo Keita , Hasegawa Yoshikazu , Kaneda Hiroyasu , Yamato Michiko , Hirotani Kenji , Miyazawa Masaaki , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

Effect of using a combination of targeting B7-H3 and PD-L1 on body weight in the murine tumor model
Supplemental legend from Lymph Node Metastases in Colon Cancer Are Polyclonal
Authors: Ulintz Peter J. , Greenson Joel K. , Wu Rong , Fearon Eric R. , Hardiman Karin M.
Published: April 2023

Supplemental legend
Figure S9 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Fig. S9. Distribution of miR-500a (both strands) expression levels measured by qPCR in paired tumor/non-tumor tissues. Normalized Cp values shown (Y axis - tumor tissue, X axis - adjacent non-tumor tissue).
Figure S8 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Fig. S8. Survival curves for SUSD3 gene expression. A) current LIBCSP study, B) METABRIC population, C) KMplot combined dataset. From left to right: global population, HR-positive (i.e. positive for ER or/and PR) patients, HR-negative (i.e. negative for both ER and PR) patients.
Figure S6 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Fig. S6. Examples of the genes that remain significant after adjusting for the Risk-Of-Recurrence for LIBCSP participants.
Table S5 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Authors: Sandulache Vlad C. , Michikawa Chieko , Kataria Pranav , Gleber-Netto Frederico O. , Bell Diana , Trivedi Sanchit , Rao Xiayu , Wang Jing , Zhao Mei , Jasser Samar , Myers Jeffrey N. , Pickering Curtis R.
Published: April 2023

Table S5 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Figure S1 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Fig. S1. Correlation between IHC-defined status and gene expression levels for estrogen receptor (ER, left panel) and progesterone receptor (PR, right panel). Each panel shows, left to right, distribution of gene expression values (vertical axis) for IHC-negative, IHC-positive and IHC-unknown groups. Red lines indicate the cut-off chosen (see below).
Supplementary Figures from Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
Authors: Wang Qiong J. , Yu Zhiya , Hanada Ken-ichi , Patel Krishna , Kleiner David , Restifo Nicholas P. , Yang James C.
Published: April 2023

Supplementary Figure 1. CD70 expression on tumor lines Supplementary Figure 2. In vivo persistence of transferred murine T cells. Body weight and cell counts of non-tumor bearing mice.
Supplemental Figure S6 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Authors: Liu Liqin , Lam Chia-Ying K. , Long Vatana , Widjaja Lusiana , Yang Yinhua , Li Hua , Jin Linda , Burke Steve , Gorlatov Sergey , Brown Jennifer , Alderson Ralph , Lewis Margaret D. , Nordstrom Jeffrey L. , Koenig Scott , Moore Paul A. , Johnson Syd , Bonvini Ezio
Published: April 2023

In vitro cytotoxicity by MGD011 supported by non-human primate T-cells
Supplemental Figure S3 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Authors: Liu Liqin , Lam Chia-Ying K. , Long Vatana , Widjaja Lusiana , Yang Yinhua , Li Hua , Jin Linda , Burke Steve , Gorlatov Sergey , Brown Jennifer , Alderson Ralph , Lewis Margaret D. , Nordstrom Jeffrey L. , Koenig Scott , Moore Paul A. , Johnson Syd , Bonvini Ezio
Published: April 2023

MGD011 mediated concentration-dependent cytotoxicity against CD19+ HBL-2 and Jeko-1 lymphoma cell lines
Supplemental Figure Legends from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Authors: Liu Liqin , Lam Chia-Ying K. , Long Vatana , Widjaja Lusiana , Yang Yinhua , Li Hua , Jin Linda , Burke Steve , Gorlatov Sergey , Brown Jennifer , Alderson Ralph , Lewis Margaret D. , Nordstrom Jeffrey L. , Koenig Scott , Moore Paul A. , Johnson Syd , Bonvini Ezio
Published: April 2023

Supplemental figure legends for supplemental figures S1, S2, S3, S4, S5, S6